VolitionRx Limited (VNRX) is a Healthcare stock trading at $0.38 (as of 2026-09-02), with a market capitalization of $3.15M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
VolitionRx Limited develops and sells blood-test solutions for clinical and veterinary settings, including assays for cancer detection and monitoring of immune response, as well as sample processing and nucleosome profiling offerings. Its technology platform, Nucleosomics, supports these tests for use in diagnosing cancers and other diseases.
Understand VolitionRx Limited: how it makes money
VolitionRx develops blood-based epigenetic tests (Nu.Q) for cancer detection, immune monitoring, and veterinary diagnostics, monetized through lab partnerships and milestone payments. Revenue is lumpy and partner-dependent, arriving in large one-off shipments rather than recurring product sales.
Every dollar of revenue traces to a single partner deal or large order landing in the quarter, so the P&L is essentially a countdown to the next milestone payment rather than a growing product base.
Business quality (Unprofitable): Pre-revenue scale: $7.3M quarterly net loss, operating margin of -1042%, and no recurring revenue stream. The business is a funded R&D program awaiting commercial inflection.
Bull case
Assay validates point-of-care path: Lateral-flow testing showed 90% correlation with the established assay, which could expand Nu.Q from centralized labs into point-of-care settings and broadly widen the addressable market.
Large-cap partnership pipeline: Volition has four signed agreements with multibillion-dollar companies and active discussions with more than a dozen others, diversifying future revenue across high-credit counterparts rather than one client.
Vet milestone nears first revenue: The feline lymphoma assay achieved 97% specificity and 86% detection, supporting a potential $5 million milestone payment that would mark a concrete step away from zero-revenue status.
Bear case
Guidance pulled, revenue unmodelable: Management withdrew 2026 revenue guidance because income remains uneven and tied to partner-dependent project timing, making it nearly impossible for investors to model when cash will actually arrive.
Losses growing despite cost cuts: Quarterly net loss increased to $7.3 million even with lower operating expenses, and the operating margin sits at -1042%, signaling the burn is accelerating relative to any incremental income.
European reimbursement still unresolved: French reimbursement for the NUQ lung cancer test remains uncertain and subject to process risk, leaving a key commercialization milestone in a major developed market in limbo.